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Classification of Vasculitis
Joseph L. Jorizzo
A working classification of necrotizing vasculitis based on size of the affected vessel is proposed. The classification proposed by Gilliam and
Fink in 1976 is a basis for the curren proposal. A revised working classification of vasculitis is presented. Small vessel necrotizing vasculitis
and larger vessel necrotizing vasculitis categories are further subdivided. Improved understanding of the basic science aspects of vasculitis
will hopefully give rise to a better consensus on the classification of vasculitis. J Invest Dermatol 100:106S–110S, 1993
A considerable portion of the now classic Medical Grand Rounds on
necrotizing vasculitis presented at The University of Texas Southwestern
Medical Center by James W. Gilliam in 1976 dealt with the classification
of necrotizing vasculitis. Aspects of this presentation have been
published (Table I) [1].
The historical context of Gilliam’s classification is important given the
confounding array of classification schemas that preceded (and followed!)
it. The classification of vasculitis remains frustratingly controversial today.
Zeek was the first to incorporate a clinicopathologic assessment
based on the size of the vessel involved in the inflammatory process in
his classification of necrotizing vasculitis in 1952 [2]. Zeek’s schema
included hypersensitivity arteritis, allergic granulomatosis, Wegener’s
granulomatosis, polyarteritis nodosa, and giant cell arteritis [3]. Other
schemas were also proposed [4,5].
Winkelmann has highlighted issues that can be considered in the
development of classification schema of vasculitis, including clinical
classification, systemic versus cutaneous, muscular-vessel versus small-
vessel disease, histopathologic features including leukocytoclastic vasculitis
versus ‘‘lymphocytic vasculitis,’’ and vasculitis showing mixed or granulo-
matous histology [6]. He also reviewed ‘‘laboratory vasculitis’’ in which
findings obtained during laboratory screening of the patient with vasculitis
can be used to develop the classification schema and also etiologic factors,
which can be relevant to classification when they are known [6].
A number of alternative classification systems have been proposed
since Gilliam’s Grand Rounds. Most of these have similarities with
Gilliam’s proposed classification, while each proponent has struggled
with various issues raised by Winkelmann [7–12]. Particularly disturbing
are the recently published American College of Rheumatology (ACR)
criteria for the classification of vasculitis [12]. Although the attempt to
develop diagnostic criteria by analyzing clinical variables in a large
patient population and then testing these criteria in other patient
populations is laudable, common sense is sometimes sacrificed in favor
of criteria that are simply reproducible. Particularly obvious problems are
the attempt to codify the histologic findings of small-vessel (‘‘hypersensi-
tivity’’) vasculitis. Fourteen biopsy criteria are listed! The use of concepts
such as ‘‘maculopapular rash,’’ ‘‘medication at onset,’’ and ‘‘eosinophils
on biopsy’’ as criteria seem particularly inappropriate to many
dermatologists, as does an entirely separate classification for Henoch-
Schonlein purpura [12]. Table II illustrates the ACR criteria ‘‘selected for
the diagnosis of hypersensitivity vasculitis,’’ which corresponds to small-
vessel necrotizing vasculitis. It is easy to criticize, however; the
development of a working classification that is clinically relevant, is
workable by various specialists, and addresses clinical features, vessel
size, histopathologic features, laboratory features, and underlying causes
of vasculitis is a goal that remains elusive. An attempt at classification
that represents an update of the classification presented by Gilliam is
presented (see Table III). Small-vessel necrotizing vasculitis is empha-
sized in the discussion that follows.
SMALL VESSEL NECROTIZING VASCULITIS
(NECROTIZING VENULITIS)
The hallmark of small-vessel necrotizing vasculitis is the diagnostic
histopathologic finding of leukocytoclastic vasculitis including endothe-
lial cell swelling, neutrophilic invasion of blood-vessel walls, leukocy-
toclasia (neutrophilic nuclear karyorrhexis), extravasation of
erythrocytes, and fibrinoid necrosis of blood vessel walls [14]. This
process has been shown to affect post capillary venules [15,16]. This
entity has been proposed as a cutaneous model for circulating immune
complex–mediated, neutrophil-induced vessel damage [17]. At the
same time, it is important to realize that the histologic findings of leuko-
cytoclastic vasculitis can occur in settings other than those due to
circulating immune complexes such as with septic or less commonly
with other emboli, with repeated cold injury, next to cutaneous ulcers, or
in associations with other cutaneous insults.
Clinical Aspects Although a spectrum of cutaneous necrotizing lesions
can be seen in patients with small-vessel necrotizing vasculitis, the
hallmark lesion is the palpable purpuric papule. These lesions occur in
crops, generally on dependent sites (Fig 1). Lesions are usually less than
1 cm in diameter, and they progress from erythema-tous macules to
purpuric papules, occasionally becoming confluent producing plaques
that may ulcerate. Lesions may be moderately symptomatic with pruritus
or pain. Associated, mild, dependent edema can also be symptomatic.
Serum sickness–like signs and symptoms such as arthralgias, arthritis,
myalgias, and fever are often associated.
Similar clinicopathologic lesions may occur in internal locations also,
presumably due to circulating immune complex–mediated vessel damage
at those sites. Classic manifestations/locations include proteinuria and/or
hematuria/kidney glomeruli; focal or diffuse, central or peripheral
neurologic manifestations/nervous system; polyarthritis/synovia; abdom-
inal pain and/or bleeding/gastrointestinal tract; pleuritis and pleural
effusion/pleura; signs and symptoms of pericardial effusion/pericardium;
and other manifestations [13,17].
Most subgroups of small-vessel necrotizing vasculitis listed in Table II
are characterized by the types of lesions listed above. Adult patients with
IgA-associated small-vessel necrotizing venulitis (Henoch-Schonlein
purpura) have, in addition, been noted to have distinctive plaque-like
lesions in a livedoid pattern [18].
Urticarial vasculitis is characterized by wheals, the individual lesions
of which persist for more than 24h. Classic lesions burn more than itch
and leave residual purpura after resolution. Lesions are distributed
randomly rather than on dependent sites [19].
Erythema elavatum diutinum is characterized by erythematous
yellowish-brown plaques that classically occur over the knuckles or
elbows. Lesions are usually chronic [20].
Nodular vasculitis is characterized by distinct nodules that represent a
suppurative panniculitis affecting primarily the calves. A deep incisional
biopsy is required to confirm the clinical diagnosis [21]. This entity, often
considered with small-vessel necrotizing vasculitis, is perhaps best
classified with larger-vessel disease.
Rheumatoid nodules are subcutaneous, firm nodules that, like
erythema elevatum diutinum, affect pressure sites [22]. The histologic
findings reveal palisading granuloma formation, a feature that has
recently been seen in association with leukocytoclastic vasculitis in
‘‘rheumatoid papules’’[23].
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Lesions of septic vasculitis tend to be acrally located (e.g., finger-tips)
and may occasionally be wedge shaped. They may be papulopustular.
Lesions are generally not as numerous as those in the patient with the
‘‘usual variety’’ of small-vessel necrotizing vasculitis [24].
Histopathologic Aspects Histopathologic features of small-vessel necro-
tizing vasculitis are characterized as leukocytoclastic vasculitis as
described above [25]. Immunoreactants (IgG, IgM, IgA, C3, C4, C
1 and
Cq) and fibrin can inconsistently be demonstrated in dermal vessel
on direct immunofluorescence microscopy, although this finding is
non-specific and is not of much use clinically [13]. The same can
be concluded about the ‘‘histamine trap test’’ originally described
by Braverman and Yen in which lesions are induced by intra-
dermal histamine injection [15]. Immunoelectron microscopic studies
have demonstrated that the post-capillary venule is the site of path-
ology in this disease and immunoreactants are demonstrable in dermal
vessels [26].
The characteristic histopathologic features of small-vessel necrotizing
vasculitis are transient. Therefore, confirmation of the clinical diagnosis
histopathologically can be difficult. Old lesions (older than 24–48h) or
treated lesions no longer show the required changes of leukocytoclastic
vasculitis, but rather show non-specific lymphocytic perivascular
changes [17]. The failure to appreciate that vasculitic lesions have
‘‘lifespans’’ and the tendency to view a pathology report as an
interpretation of a static event have, in my view, led to much of the
confusion that exists in classifications of vasculitis based on histopatho-
logy, including some of the confusion in the new ACR criteria [12].
Table I. Classification of Necrotizing Vasculitides by
Gilliam and Fink Presented at Medical Grand Rounds
on September 9, 1976 at University of Texas
Southwestern Medical Center
I. Leukocytoclastic Vasculitis (hypersensitivity angiitis or allergic
vasculitis)
A. Schonlein-Henoch purpura
B. Hypocomplementemic vasculitis
C. Essential mixed cryoglobulinemia
D. Other disease-related dermal vasculitides
II. Rheumatic Vasculitis
A. Systemic lupus erythematosus
B. Rheumatoid vasculitis
C. Scleroderma
D. Dermatomyositis
E. Acute rheumatic fever
III. Granulomatous Vasculitis
A. Churg and Strauss allergic granulomatous angiitis
B. Wegener’s granulomatosis
C. Limited Wegener’s
IV. Polyarteritis Nodosa
A. Classic type
B. Limited type (skin and muscle)
C. Hepatitis B antigen associated vasculitis
D. Vasculitis in drug addicts
E. Vasculitis following serous otitis media
V. Giant Cell Arteritis
A. Temporal arteritis
B. Polymyalgia rheumatica
C. Takayasu’s disease
Table II. 1900 American College of Rheumatology
Criteria For Hypersensitivity Vasculitis (Traditional
Format)a
1. Age at disease onset 416 years
2. Medication at disease onset
3. Palpable purpura
4. Maculopapular rash
5. Biopsy including arteriole and venule with histologic changes showing
granulocytes in a perivascular or extravascular location
aAt least three of five criteria must be present. The presence of three of five
criteria was associated with a specificity of 83.9% and a sensitivity of
71.0% [12].
Table III. Proposed Working Classification of
Vasculitis
I. Small-vessel necrotizing vasculitis
A. Necrotizing venulitis
B. Henoch-Scholein purpura
C. Essential mixed cryoglobulinemia
D. Waldenstom’s hypergammaglobulinemic purpura
E. Associated with collagen vascular disease
F. Urticarial vasculitis
G. Erythema elevatum diutinum
H. Rheumatoid nodules
I. Reactive leprosy
J. Septic vasculitis
II. Larger-vessel necrotizing vasculitis
A. Polyarteritis nodosa
1. Benign cutaneous form
2. Systemic form
B. Granulomatous vasculitis
1. Wegener’s granulomatosis
2. Allergic granulomatosis
3. lymphomatoid granulomatosis
C. Giant cell arteritis
1. Temporal arteritis
2. Takayasu’s disease
D. Larger-vessel vasculitis with collagen vascular disease
E. Nodular vasculitis
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Patient Evaluation A three-stage approach to evaluation of the patient
with suspected small-vessel necrotizing vasculitis can be employed. The
physician must confirm the diagnosis histologically, determine the extent
of the disease process, and search for underlying disease.
Confirmation of the clinical diagnosis histologically is complicated by
the tendency of patients to present to the dermatologist with older lesions
and/or after aggressive systemic therapy. A commitment to eventual histo-
logic confirmation and patience are necessary to ‘‘catch the right lesion at
the right time’’ to demonstrate leukocytoclastic vasculitis histologically.
Systemic manifestations are not uncommon in the patient presenting
to the dermatologist. The wide array of signs, symptoms, and possible
target organs for circulating immune complex – mediated injury have
been reviewed. A complete history and physical examination as well as
screening laboratory tests are required for patients with small-vessel
necrotizing vasculitis. The dermatologist may often wish to work in
conjunction with the patient’s primary-care physician or an appropriate
pediatric or medical subspecialist to achieve this end. Evaluation should
be directed at the systems that can be affected in this disease. Urinalysis
and renal function testing are particularly relevant.
The underlying cause of small-vessel necrotizing vasculitis is detected
in only 39–61% of patients [13]. One should realize that absolute proof of
etiology for a given agent is difficult. Even if immunoblotting techniques
identify a specific antigen in association with circulating immune
complexes in the circulation and the same antigen is detected by
immunoperoxidase or other techniques in tissue, cause and effect is not
unequivocally proved. Rather than memorizing a list of implicated
etiologic agents, it might be easiest to think of possible causes as falling
into three categories: drugs, infectious agents, or diseases associated with
immune complexes. Examples of implicated drugs include aspirin,
penicillin, thiazides, and sulfonamides [13]. Examples of the most accepted
associated infectious etiologic agents include streptococcal species,
Hepatitis B, and Mycobacterium tuberculosis [13]. Disease associated
with immune complexes is a designation to include conditions such as
various malignancies, collagen vascular diseases (especially systemic lupus
erythematosus, childhood dermatomyositis, and rheumatoid arthritis),
inflammatory bowel disease, and chronic active hepatitis [13].
A discussion of the therapeutic approach to the patient with small-
vessel necrotizing vasculitis is beyond the scope of this review. No
systemic or topical therapy has been subjected to the scrutiny of a
prospective placebo-controlled, double-blind study. The disease may
follow an acute, chronic, or relapsing course [27] and may be limited to
the skin without progression to systemic disease [28]. Cutaneous disease
alone may be left untreated or agents such as oral antibiotics, colchicine,
or sulfones may be used. Treatment for systemic involvement can include
systemic corticosteroids (single dose, split dose, or pulse regimen), low-
dose weekly methotrexate, azathioprine, cyclophosphamide, or even
cyclosporine.
LARGER VESSEL VASCULITIS
Polyarteritis Nodosa — Systemic Form Systemic polyarteritis nodosa is a
multisystem disease that can be life threatening. Cutaneous lesions occur in
only one-fifth to one-half of patients, with small-vessel type (palpable
purpura) lesions being the most common manifestation [29]. These lesions
may occur due to a ‘‘spillover’’ of circulating immune complexes into post-
capillary venules. This is at least part of the reason for the early confusion in
classification of vasculitis with failure to distinguish small-vessel necrotizing
vasculitis and polyarteritis nodosa. The more diagnostic cutaneous lesions
of which suggest larger vessel (e.g., muscular artery) involvement on
clinical examination are large ‘‘punctate’’ cutaneous ulcers, digital
gangrene, or livedo reticularis with ulcerating nodules (Fig 2).
Systemic involvement can include renal disease with arterial
hypertension, which occurs in three-fourths of patients and is the
primary cause of death in patients with polyarteritis nodosa [30].
Dysrythmias, cardiac failure, and cardiac infarction may also prove fatal
[31]. Ocular, gastrointestinal, central and peripheral nervous system, and
arthritic complications are the most frequent other manifestations.
Panarteritis of muscular arteries with secondary aneurysmal changes
are the typical histologic features [32,33]. Not only are the ‘‘lesions
with lifespans’’ issues discussed above relevant, but histopathologic
confirmation of the diagnosis of polyarteritis nodosa is further compli-
cated by the reduced accessibility of muscular arteries to skin biopsy, by
the occurrence of the diagnostic lesion proximal to the site of cutaneous
infarction, and by the urgency of need for treatment. Arteriographic
demonstration of aneurismal changes in renal or mesenteric arteries can
be diagnostic if histologic confirmation is not possible.
Most of the underlying causes outlined for small-vessel necrotizing
vasculitis are also relevant for polyarteritis nodosa. Hepatitis B might be a
particularly relevant cause [34].
Therapy with systemic corticosteroids only improved the 5-year
survival in this disease to 50%. Cyclophosphamide therapy has greatly
improved 5-year survival to the 70–90% range.
Polyarteritis Nodosa – Benign Cutaneous Form A benign cutaneous form
of polyarteritis nodosa characterized by painful, ulcerating cutaneous
nodules surrounding a necrotizing livedo reticularis pattern has been
described [35]. Lesions occur primarily on the extremities. Histopathologic
findings in the skin are identical to those seen in the systemic form of
polyarteritis nodosa [36]. Although the disease is not life threatening,
systemic therapy is often undertaken due to the painful nature of the lesions.
The incidence and exact relationship of benign cutaneous polyarteritis
nodosa to the systemic form of the disease await further clarification.
Granulomatous Vasculitis — Wegener’s Granulomatosis Wegener’s
granulomatosis is a rare, multisystem disease characterized by a
necrotizing granulomatous vasculitis. The upper respiratory tract and
kidneys are primary sites of involvement [37]. The classic cutaneous
lesions are pyoderma gangrenosum-like lesions that may occur anywhere
Figure 1. Palpable purpuric papules in an acral distribution suggested a
diagnosis of small-vessel necrotizing vasculitis. Biopsy of a lesion revealed the
confirmatory finding of leukocytoclastic vasculitis.
Figure 2. Cutaneous ulceration in a pattern suggestive of larger vessel
vasculitis in a patient who proved to have systemic polyarteritis nodosa.
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but are particularly suggestive of the diagnosis when located in a
periorificial distribution [38,39]. Palpable purpuric lesions are also
common, as they are in polyarteritis nodosa. These lesions result from
post-capillary venular vasculitis.
Systemic involvement is often heralded by necrotizing granulo-
matous lesions of the upper respiratory tract. The nose, nasopharynx,
tongue, trachea, and bronchi may be affected. Focal necrotizing
glomerulonephritis with extra glomerular granulomas is another classic
feature. Antineutrophil cytoplasmic antibody may have a special role in
diagnosis [40].
Survival prior to recent therapeutic advances was as low as 10% at 2
years. Newer regimens using cyclophosphamide and prednisone have
resulted in up to 90% 5-year survival rates and to apparent cures [37].
Not all centers support quite such high success rates [41].
Granulomatous Vasculitis — Allergic Granulomatosis of Churg and
Strauss Churg and Strauss separated allergic granulomatosis from
polyarteritis nodosa in the early 1950s. Patients usually have a history
of chronic asthma. They develop pulmonary infiltrates and a peripheral
blood eosinophilia that may be in the 10–20% range. Small arteries and
venules are affected by a vasculitis and palisading granulomas surround
necrotic areas of connective tissue.
Classically, involvement of two or more non-pulmonary organs is
required for diagnosis. Cutaneous findings usually include lesions
associated with larger-vessel vasculitis such as cutaneous ulcers and
subcutaneous nodules but, as with the other larger-vessel vasculitides,
palpable purpura due to post-capillary venular involvement can also be
seen. Up to 70% of patients have cutaneous lesions [42,43].
Systemic corticosteroids are a mainstay of therapy. A second im-
munosuppressive agent may be required [42,43]. The prognosis for
untreated patients is generally better than that for polyarteritis nodosa or
Wegener’s granulomatosis.
Granulomatous Vasculitis — Lymphomatoid Granulomatosis Lympho-
matoid granulomatosis is a systemic disorder that represents an
angioinvasive lymphohistiocytic process that involves the lungs but can
affect virtually any organ, especially the central nervous system, kidneys,
and the skin. The skin may be affected in 20% of patients [44,45]. The
diagnosis can be confirmed with skin biopsy. Atypical cells may show
bizarre cytologic features. Cyclophosphamide and prednisone may
produce long-term remission [46]. A significant percentage of patients
develop widespread lymphoma.
Giant Cell Arteritis — Temporal Arteritis Large or medium-sized arteritis
in the temporal region are the most common site for giant cell arteritis,
which can be unilateral or bilateral. Elderly Caucasian women are primarily
affected. Fever, headache, polymyalgia rheumatica, anemia, and elevated
erythrocyte sedimentation rate are common features [47]. The classic
cutaneous lesion is scalp ulcer-ation [48]. Retinal arteritis can lead to
blindness. The histopatho-logic features include a panarteritis with multi-
nucleated giant cells. Systemic corticosteroid therapy is often required.
Giant Cell Arteritis — Takayasu’s Disease Takayasu’s arteritis is a chronic
arteritis that affects the aorta and its main branches. Systemic features may
be widespread and depend on the location and severity of involvement of
the vascular bed that is affected [49]. Cutaneous lesions include palpable
purpura, ulcers, or pyoderma gangrenosum-like lesions [50]. Granuloma-
tous arteritis followed by fibrosis and stenosis is seen histologically. Systemic
prednisone (often with a second immunosuppressive agent) is the principle
therapy. Surgical treatment may also be required.
Vasculitis in Patients with Collagen Vascular Diseases A thorough
discussion of vasculitis in collagen vascular diseases is beyond the scope
of this review. These diseases are possible underlying causes of small-
vessel necrotizing vasculitis as discussed above. Larger vessel involve-
ment may be suggested clinically by large cutaneous ulcers, digital
gangrene, necrosing livedo reticularis, or pyoderma gangrenosum–like
lesions. Other causes of peripheral gangrene and the other cutaneous
findings mentioned must be excluded. Emboli of various types, sludging
syndromes (e.g., cryoglobulins or macroglobulins), and vasospasm must
be excluded in patients with collagen vascular disorders who develop
these cutaneous findings before a diagnosis of large-vessel vasculitis is
accepted. Histologic confirmation of the diagnosis of vasculitis should
always be sought. Larger vessel vasculitis is a particularly relevant feature
of rheumatoid arthritis [51], systemic lupus erythematosus [52], and
juvenile dermatomyositis [53].
Nodular Vasculitis Nodular vasculitis was originally called erythema
induratum. Patients develop red, indurated plaques on the lower legs.
Older lesions may suppurate. Vasculitis of a subcutaneous artery or
vein is found in the center of an area of lobular panniculitis. Although
initially described in patients with tuberculosis, a host of underlying
causes including drugs, infections, or diseases associated with immune
complexes are now considered as possible underlying causes of nodular
vasculitis [54].
VASCULITIS-RELATED SYNDROMES
Selected other vessel-based inflammatory dermatoses sometimes con-
fused with vasculitis are listed in Table IV. The designation vasculitis
should not be applied to these conditions despite inflammation of
vessels, which characterizes these conditions histologically.
SUMMARY
The classification of vasculitis remains controversial in 1991, with
various authors struggling with how to incorporate histopathologic
features, size of affected blood vessels, etiology, and other factors in their
classification schemas. Dr. James Gilliam was a significant player in the
attempt to classify vasculitis. We can hope that a new generation of basic
and clinical investigators, many influenced by Jim Gilliam, can achieve a
better understanding of the pathogenesis of various vasculitis-related
syndromes and that this understanding will facilitate future classification.
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